Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxte...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-023-00519-0 |
| _version_ | 1797429039132049408 |
|---|---|
| author | Laura Alder Dario Trapani Claire Bradbury Amanda E. D. Van Swearingen Sara M. Tolaney Mustafa Khasraw Carey K. Anders Christopher D. Lascola Liangge Hsu Nancy U. Lin Sarah Sammons |
| author_facet | Laura Alder Dario Trapani Claire Bradbury Amanda E. D. Van Swearingen Sara M. Tolaney Mustafa Khasraw Carey K. Anders Christopher D. Lascola Liangge Hsu Nancy U. Lin Sarah Sammons |
| author_sort | Laura Alder |
| collection | DOAJ |
| description | Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active. |
| first_indexed | 2024-03-09T09:07:25Z |
| format | Article |
| id | doaj.art-c1b60de0ae2644269e08499f1c0de607 |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-09T09:07:25Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-c1b60de0ae2644269e08499f1c0de6072023-12-02T10:02:51ZengNature Portfolionpj Breast Cancer2374-46772023-03-01911510.1038/s41523-023-00519-0Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecanLaura Alder0Dario Trapani1Claire Bradbury2Amanda E. D. Van Swearingen3Sara M. Tolaney4Mustafa Khasraw5Carey K. Anders6Christopher D. Lascola7Liangge Hsu8Nancy U. Lin9Sarah Sammons10Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke UniversityMedical Oncology, Dana-Farber Cancer InstituteDepartment of Biostatistics, Duke Cancer Institute, Duke UniversityDivision of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke UniversityMedical Oncology, Dana-Farber Cancer InstituteDivision of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke UniversityDivision of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke UniversityDepartment of Radiology, Duke UniversityHarvard Medical SchoolMedical Oncology, Dana-Farber Cancer InstituteDivision of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke UniversityAbstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.https://doi.org/10.1038/s41523-023-00519-0 |
| spellingShingle | Laura Alder Dario Trapani Claire Bradbury Amanda E. D. Van Swearingen Sara M. Tolaney Mustafa Khasraw Carey K. Anders Christopher D. Lascola Liangge Hsu Nancy U. Lin Sarah Sammons Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan npj Breast Cancer |
| title | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan |
| title_full | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan |
| title_fullStr | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan |
| title_full_unstemmed | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan |
| title_short | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan |
| title_sort | durable responses in patients with her2 breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan |
| url | https://doi.org/10.1038/s41523-023-00519-0 |
| work_keys_str_mv | AT lauraalder durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT dariotrapani durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT clairebradbury durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT amandaedvanswearingen durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT saramtolaney durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT mustafakhasraw durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT careykanders durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT christopherdlascola durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT lianggehsu durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT nancyulin durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan AT sarahsammons durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan |